Immunohistochemical studies with a monoclonal antibody on the distribution of phosphophoryn in predentin and dentin

Summary A monoclonal antibody was raised against phosphoryn, a unique noncollagenous phosphoprotein in dentin. Mouse myeloma NS-I cells were fused with spleen cells obtained from BALB/c mice immunized with phosphophoryn from fetal calf tooth germs. Mice inoculated with the hybridoma produced ascites fluid containing the antibody and this reacted only with a band of phosphophoryn transblotted from polyacrylamide gel. Immunohistochemical studies with the antibody showed that phosphophoryn was present in odontoblasts, odontoblastic processes and dentin, but not in the matrix of predentin, and that the phosphophoryn content of the dentin layer was high at and around the predentin-dentin junction and gradually decreased toward the enamel layer. The area corresponding to mantle dentin was not stained with the antibody.     

Production of a monoclonal antibody against human amelogenin

The extracellular organic matrix of developing human enamel is composed of two major classes of proteins, the hydrophobic amelogenins and the acidic enamelins. In order to identify, purify, and characterize the amelogenins from this complex mixture of proteins, and to study their ultrastructural localization and their pathways of synthesis, secretion, and degradation, specific and sensitive probes are needed. In the present paper the production of a monoclonal antibody against human amelogenin employing an intrasplenic primary immunization protocol is described. The monoclonal antibody produced is IgM and recognizes major human amelogenin protein bands in Western immunoblot assays. It also recognizes amelogenin protein bands from other species, specifically bovine and porcine. Indirect immunohistochemical studies showed the monoclonal antibody to react specifically with the extracellular matrix of human developing enamel. It did not react with the underlying dentin layer.     

Sclerostin单克隆抗体：即将出现的治疗骨质疏松症的新药物

骨质疏松是一种很常见的骨病,主要表现为单位体积内骨量减少、骨密度及骨强度的下降,加大骨折的风险增加.目前骨质疏松的药物治疗方法主要有:(1)激素替代治疗,(2)钙剂及维生素D,(3)抑制骨吸收,(4)促进骨形成,(5)中药治疗.Sclerostin是由骨细胞分泌的一种糖蛋白,拮抗性结合到LRP6和LRP6,阻断成骨细胞中Wnt信号/β-catenin信号,从而抑制成骨细胞分化、活动和生存.其作用机制使得Sclerostin成为治疗骨质疏松的一个新的靶点.目前,作用于Sclerostin的Sclerostin单克隆抗体已经进行了动物实验及临床前实验.实验结果显示Sclerostin单克隆抗体能促进骨形成,增加骨密度.目前Sclerostin单克隆抗体的安全性仍需进一步研究,但对治疗人类骨质疏松症有广阔的前景.     

Extracellular processing of dentin matrix protein in the mineralizing odontoblast culture

Odontoblasts that we prepared from bovine incisors produced a dentin-specific protein, phosphophoryn, and accumulated it in mineralized nodules. The time course of mineralization was detected by measuring osteocalcin and mineral in the nodules. The sequence of developmental expression of proteins in this mineralizing dentin cell culture is very similar to that in bone cells, suggesting a common mechanism for matrix mineralization in bone and dentin. Casein kinase II, which phosphorylates bone phosphoproteins and dentin phosphophoryn, also emerges coinciding with the initiation of mineralization. Furthermore, we have detected extracellular phosphorylation by casein kinase II of a dentin protein of M_r 60,000, which we recovered from the phosphophoryn fraction in CaCl₂ precipitate.     

Preparation of monoclonal antibodies to chicken bone phosphoproteins

Summary Monoclonal and polyclonal antibodies were raised against 150k, 60k, 32k, and 15k phosphoprotein components of 14-week chicken bone. Hybridomas were prepared by immunizing Balb/c mice with 150k, 60k, or 32k phosphoproteins followed by fusion of their spleen cells with X63-Ag8.653 myeloma cells. Polyclonal antibodies to the 60k, 32k, and 15k phosphoprotein components were produced in immunized rabbits. Immunological cross-reactivity between antigen and antibody was examined by enzyme-linked immunosorbent assay (ELISA) and dot-blotting. There was cross-reactivity between the 150k, 32k, and 15k phosphoprotein components and between the 150k, 90K, and 60k components. The antibodies raised against 60k component do not bind 32k and 15k antigens.     

应用单克隆抗体诊断泌尿系统肿瘤骨髓内的微转移

以抗细胞角质蛋白－１８（ＣＫ－１８）单克隆抗体为标记抗体，采用免疫细胞化学染色方法研究了６４例泌尿系统肿瘤在骨髓中的微转移，发现２８．１％的病人有骨髓微小转移。此方法可以将癌细胞染成红色，显微镜下很容易与正常骨髓细胞相区别。我们认为此方法敏感、准确、实用，同一种方法可用于不同癌症患者的检查。     

抗内毒素类脂A单克隆抗体对烧伤脓毒症大鼠的保护作用

采用我所研究制备的抗内毒素类脂Ａ单克隆抗体（ｍＡｂ）观察了其对攻菌后动物的保护作用，并采用３０％Ⅲ度ＴＢＳＡ烧伤大鼠模型注射内毒素，模拟临床烧伤脓毒症，旨在为临床防治提供理论依据。实验动物分烧毒组、治疗组及对照组，于伤后不同时相点观察血浆ＬＰＳ、ＴＮＦ的动态变化，同时作内脏的光镜及电镜形态学检查。结果表明：ｍＡｂ除在体外可与多种Ｇ－杆菌及纯化的内毒素反应外，细菌攻击前后注入ｍＡｂ均能有效地提高感染动物的存活率，并可明显降低模拟烧伤脓毒症大鼠血中内毒素，减少ＴＮＦ的分泌。光、电镜观察证实，可减轻机体的损害效应。提示：抗类脂Ａ单克隆抗体是一种有效的治疗烧伤脓毒症的免疫制剂。     

抗内毒素类脂A单克隆抗体对烧伤脓毒症大鼠的保护作用

采用我所研究制备的抗内毒素类脂 A 单克隆抗体(mAb)观察了其对攻菌后动物的保护作用,并采用30%Ⅲ度 TBSA 烧伤大鼠模型注射内毒素,模拟临床烧伤脓毒症,旨在为临床防治提供理论依据。实验动物分烧毒组、治疗组及对照组,于伤后不同时相点观察血浆 LPS、TNF 的动态变化,同时作内脏的光镜及电镜形态学检查。结果表明:mAb 除在体外可与多种 G~-杆菌及纯化的内毒素反应外,细菌攻击前后注入 mAb 均能有效地提高感染动物的存活率,并可明显降低模拟烧伤脓毒症大鼠血中内毒素,减少 TNF 的分泌。光、电镜观察证实,可减轻机体的损害效应。提示:抗类脂 A 单克隆抗体是一种有效的治疗烧伤脓毒症的免疫制剂。     

131Ⅰ-肿瘤细胞核人鼠嵌合单抗脑胶质瘤瘤内放免治疗研究

目的　研究13 1I chTNT(13 1I 肿瘤细胞核人鼠嵌合单抗 )通过局部化疗囊注入胶质瘤瘤腔内 ,行瘤内放免治疗。方法　选择全部经手术病理证实的脑胶质瘤患者 5 6例 ,其中胶质母细胞瘤 3 4例 ,星形细胞瘤 2 2例。第 1次手术者 2 0例 ,余为复发性手术。术中瘤腔内置入化疗囊 ,手术后 7d囊内注入13 1I chTNT 1.1× 10 3 Bq ,15d后重复注入 1次。 结果　于末次注药后 2个月复查CT或MRI ,随访期 6个月～ 2年 2个月 ,完全缓解 2 1例 (3 7.5 % ) ,部分缓解 2 4例 (4 2 .8% ) ,临床症状减轻 ,病情稳定 7例 (12 .5 % ) ,病情恶化 4例 (7.1% )。结论　单克隆抗体与13 1I交联后靶向于肿瘤细胞核 ,和瘤体特异性结合 ,并将其荷载的放射性核素输送到肿瘤细胞内 ,由内向外摧毁肿瘤。临床疗效满意 ,优于其他类型的瘤内近距离放疗。     

Radioimmunoscintigraphy using an anti-prostate monoclonal antibody (E4): a dosimetric evaluation

The aim of this study was to evaluate different strategies to increase the tumour radiation dose for experimental radioimmunotherapy using ¹²⁵I-labelled monoclonal antibody (MAb) E4 in a nude mice model xenografted with DU-145 tumours. The effects from a single injection of the ¹²⁵I-labelled MAb E4, the same total amount of radiolabelled MAb E4 divided into three repeated injections, and the effect of pre-targeting with non-labelled MAb E4 for reducing the amount of shed antigen were investigated. Based on repetitive quantitative radioimmunoscintigraphies, calculation of the tumour radiation dose delivered from the ¹²⁵I-nuclide was performed for each strategy. The single injection strategy without pretargeting rendered the highest mean tumour radiation dose, i.e. 0.23 Gy/MBq. Pretargeting with non-labelled MAb E4 before a single injection of [¹²⁵I]E4 resulted in a slightly lower mean tumour radiation dose, i.e. 0.19 Gy/MBq, compared to the single injection alone. An even lower mean tumour radiation dose, i.e. 0.14 Gy/MBq, was obtained when the same total administered amount of activity was divided into three separate injections given in 10-day intervals. We concluded that the single injection strategy is the most efficient when using MAb E4 in this tumour model. The tumour radiation doses were not increased by dividing the same amount of activity into three injections or by pretargeting with non-labelled MAb E4. Received: 30 October 2000 / Accepted: 23 February 2001     

金黄色葡萄球菌肠毒素B单克隆抗体对烫伤脓毒症大鼠急性肺损伤的影响

目的探讨金黄色葡萄球菌(简称金葡菌)肠毒素B(SEB)单克隆抗体(单抗)对烫伤脓毒症大鼠急性肺损伤的保护作用。方法雄性Wistar大鼠56只随机分为正常对照组(n=10)、烫伤对照组(n=10)、烫伤后金葡菌感染组(n=20)和SEB单克隆抗体(单抗)拮抗组(n=16)。测定肺组织SEB水平、髓过氧化物酶(MPO)活性、肿瘤坏死因子(TNF)-α和干扰素(IFN)-γ表达的改变。结果烫伤后金葡菌脓毒症动物肺脏SEB含量明显升高,伤后2、6h分别为66.85ng/g组织和92.46ng/g组织,与正常对照组(14.26ng/g组织)和烫伤对照组(17.32ng/g组织)相比均为P＜0.01;同时,肺组织MPO活性显著增强,峰值可达7.39U/g组织,与正常对照组(2.09U/g组织)相比P＜0.05。与之相应,肺组织MPO活性显著增强(P<0.05)。同时,局部组织IFN-γ和TNF-α基因及其蛋白质表达明显上调(P<0.05),并与肺脏SEB含量呈高度正相关(分别为r=0.9207、P=0.0033和r=0.8142、P=0.0258)。SEB单抗早期干预可有效降低肺组织中SEB含量,并显著抑制IFN-γ和TNF-α的产生,肺脏病理改变亦明显减轻。结论SEB单抗干预可抑制IFN-γ和TNF-α等炎症介质的产生,从而显著减轻烫伤后金葡菌对机体的损害。     

抗肝肠钙粘连蛋白单克隆抗体对肝癌细胞生物学行为的影响

目的 观察抗肝肠钙粘连蛋白(CDH17)单克隆抗体Lic5对肝癌细胞生物学行为的影响.方法 Western blot和实时定量聚合酶链反应(PCR)检测细胞株MHCC97H、MHCC97L、PLC/PRF/5及MIHA中CDH17的表达.噻唑蓝(MTT)比色法、细胞划痕法、Transwell法及平板克隆法检测Lic5对肝癌细胞生物学行为的影响.结果 CDH17仅在细胞株MHCC97H、MHCC97L中表达,Lic5可结合肝癌细胞表面的CDH17,并抑制CDH17表达.Lic5 50mg/L组、100mg/L组、小鼠IgG组4 d细胞增殖抑制率在MHCC97H为26.1%、43.6%、6.4%,MHCC97L为26.0%、40.7%、7.7%;Lic5100mg/L组、小鼠IgG组、磷酸盐缓冲液(PBS)组48h细胞迁移抑制率在MHCC97H为36.7%、8.4%、5.6%,MHCC97L为42.3%、10.2%、7.4%(P＜0.05);穿膜细胞数在MHCC97H为(39.20±9.56)、(106.50±7.56)、(96.60±13.02)个,MHCC97L为(26.00±8.61)、(86.00±10.26)、(90.40±12.04)(P＜0.05);克隆形成数在MHCC97H为(59.30±11.68)、(141.70±19.40)、(150.30±14.64),MHCC97L为(57.20±10.21)、(132.50±9.07)、(121.70±11.93)(P＜0.01).Lic5对PLC/PRF/5及MIHA细胞的生物学行为无明显影响.结论 单克隆抗体Lic5能够下调肝癌细胞CDH17表达,抑制肝癌细胞的增殖、迁移、侵袭和克隆形成能力.

Abstract：

Objective To investigate the effect of monoclonal antibody against liver-intestine cadherin (CDH17) on the cell proliferation, migration, invasion and colony formation of hepatocellular carcinoma cell lines. Methods Hepatocellular carcinoma cell lines MHCC97H, MHCC97L, PLC/PRF/5 and MIHA were examined for CDH17 expression by Western blotting and quantitative real-time polymerase chain reaction (PGR). The combination capacity between bepatocellular carcinoma cell lines and monoclonal antibody Lic5 was detected by the way of immunofluorescence staining. The cell lines were treated with Lic5, PBS and mouse IgG respectively. Methyl thiazol tetrazolium (MTT) assay, wound healing assay, Transwell invasion assay and colony formation assay were used to study the changes in cell proliferation, migration, invasion and colony formation of hepatocellular carcinoma cell lines. Results High expression level of CDH17 was detected in MHCC97H and MHCC97L cell lines. CDH17 protein level was down-regulated but there was no significant effect on CDH17 mRNA after treatment with Lie5 in MHCC97H and MHCC97L. Cellular growth rate of MHCC97H in Lic5 (50 mg/L), Lic5 ( 100 mg/L) and mouse IgG groups was decreased by 26. 1%, 43.6% and 6. 4%, and by 26. 0%, 40. 7% and 7. 7% in MHCC97L on the 4th day respectively (P ＜0. 05 ). The inhibition rate of cell migration at 48 h was 36. 7%, 8. 4% and 5.6% in Lic5 ( 100 mg/L), mouse IgG and PBS groups in MHCC97H, and 42. 3%, 10. 2% and 7. 4% in MHCC97L respectively ( P ＜ 0. 05 ). The number of invasion cells was ( 39. 20 t 9. 56),(106.50±7.56) and (96.60±13.02) in MHCC97H, and (26.00±8.61), (86.00±10.26) and (90.40±12.04) in MHCC97L in Lic5 (50 mg/L), Lic5 (100 mg/L) and mouse IgG groups, respectively (P ＜ 0. 05 ). The number of colony formation was ( 59. 30 ± 11.68 ), ( 141.70 ± 19. 40 ) and (150.30 ±14.64) in MHCC97H, and (57.20 ± 10.21), (132.50 ±9.07) and (121.70 ±11.93) in MHCC97L in Lie5 (50 mg/L), Lic5 (100 mg/L) and mouse IgG groups, respectively (P＜ 0. 01 ).There was no significant difference between Lic5 treatment groups and controls in PLC/PRF/5 and MIHA cell lines. Conclusion The anti-CDH17 monoclonal antibody Lic5 can down-regulate CDH17 expression and inhibit the cell proliferation, migration, invasion and colony formation in hepatocellular carcinoma cell lines.     

抗人乳腺癌单抗M4G3在隐性乳腺癌诊断中的应用

目的 探讨抗人乳腺癌单克隆抗体M4G3在以腋淋巴结转移癌为首发症状的隐性乳腺癌诊断中的应用。方法 对切检为腋淋巴结转移癌而乳腺内未触及肿物的62例做M4G3免疫组织化学检测，并对其中M4G3阳性病例做全乳腺大切片检查，寻找乳腺内原发癌灶。结果 M4G3阳性58例(93．55％58／62)；乳腺内原发灶总检出率84．62％(44／52)；M4G3与雌激素受体／孕激素受体检测结果呈正相关(r1=0．394，P1=0．026；r2=0．357，P2=0．045)；随访结果表明M4G3阳性患者的原发灶在乳腺内。结论 抗人乳腺癌单克隆抗体M4G3检测在以腋淋巴结转移癌为首发症状的隐性乳腺癌的诊断中有重要临床价值，还需辅以全乳腺大切片检查配合诊断。     

A monoclonal antibody (1G10) recognizes a novel human mesangial antigen.

We have identified a unique mesangial matrix protein of the human glomerulus by using a monoclonal antibody, 1G10, generated against culture human glomerular cells. By immunofluorescence, the antigen recognized by 1G10 (1G10 antigen) is present in mesangium and smooth muscle tissue and cannot be detected in any other tissue examined. Immunoelectron microscopy of glomeruli indicated that 1G10 antigen is present exclusively in the mesangial matrix at the endothelial-mesangial interface. The 1G10 antigen is also expressed by cultured mesangial cells, but not by cultured glomerular epithelial cells, umbilical endothelial cells or fibroblasts. 1G10 did not react with the mesangial matrix proteins [fibronectin (FN), laminin (LAM), collagen types I, III, IV, V, and VI (Col I, III, IV, V, VI), heparin sulfate proteoglycan (HSPG), or thrombospondin (TS)] present under normal and diseased states or smooth muscle antigens (myosin, actin), but did react with a 4 M urea extract of renal cortex and a 0.3% deoxycholate extract of isolated glomeruli. Two dimensional immunoblot analysis using the urea extract demonstrated the binding of 1G10 to an approximately 200 KDa polypeptide with pI 6.0. On one dimensional immunoblot this band did not show cross react with polyclonal antisera to FN, LAM, Col IV, V, VI, HSPG or TS. This mesangial matrix component is trypsin and periodate sensitive, suggesting that it has the character of glycoprotein. In renal biopsy specimens from patients with mesangial proliferative glomerulonephritis (GN) and membranoproliferative GN, the expression of the 1G10 antigen increased along with mesangial hypercellularity or increased accumulation of mesangial matrix, but decreased in completely sclerosed glomeruli. No significant changes in 1G10 antigen expression was observed in membranous GN or minimal change nephrosis compared to normal glomeruli. This study suggests that the 1G10 antigen may not only be a useful marker for the clinical assessment of GN, but may also serve as a potential tool for the study of the pathogenesis of glomerular diseases characterized by cellular proliferation and mesangial matrix expansion.     

Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III–IV acute graft-versus-host disease

The in vivo efficacy of 25.3 monoclonal antibody (mAb) directed against human LFA1 molecule was assessed in ten patients with steroid-resistant grade III–IV acute graft-versus-host disease (AGVHD). These patients received non-T-cell-depleted allogeneic bone marrow transplantation for aplastic anemia in two cases and hematologic malignancies in eight cases. Five grafts were fully matched, three were one antigen-mismatched, and two were two antigen-mismatched. Despite GVHD prophylaxis with cyclosporin A and short-term methotrexate, AGVHD occurred after a median of 24 days and clearly progressed under prednisone (median 2 mg/kg), given for a median of 12 days. 25.3 mAb was given at a dosage of 0.1 mg/kg in a 4-h perfusion for five daily doses without any clinical or biological side effects. Thirty percent of the patients experienced a reduction in the overall grading with two complete responses. Partial response in at least one involved organ (mostly skin) occurred in 80% of the patients. However, seven out of the eight responding patients experienced a new episode of AGVHD. This observation, which confirms that inhibiting a functional molecule is as efficient as a cytolytic therapy, offers an alternative strategy to antithymocyte globulin (ATG) and cytotoxic mAb in controlling steroid-resistant GVHD.     

抗表皮生长因子受体单克隆抗体对人胰腺癌裸鼠模型的化疗增敏作用

目的 观察鼠抗人EGFR单克隆抗体联合5-氟尿嘧啶(5-Fu)、健择对裸鼠胰腺癌化疗效果的影响.方法 将人胰腺癌肿瘤细胞悬液注射于裸鼠背部皮下,建立肿瘤模型.干预组腹腔分别注射鼠抗人EGFR单克隆抗体(MMAb-2)、5-Fu、健择及其配伍联合用药;对照组腹腔注射生理盐水.干预4周后处死裸鼠,切取肿瘤,测量瘤体积,取肿瘤组织送病理学检查;免疫组化法检测肿瘤组织中bax、bcl-2的表达;免疫荧光法检测肿瘤组织中细胞凋亡指数,评价干预效果.结果 5-Fu、健择联合应用MMAb-2对裸鼠胰腺癌细胞增殖的抑制作用明显增强(P＜0.05),且能提高裸鼠胰腺癌细胞凋亡率(P＜0.05).结论 抗EGFR单克隆抗体能有效提高化疗药物5-Fu、健择对裸鼠胰腺癌细胞抑制作用的敏感性,可明显提高胰腺癌的化疗效果.     

整合素αvβ3单克隆抗体对人胆管癌肿瘤血管生成的抑制作用

目的　研究整合素αvβ3单克隆抗体抗人胆管癌血管生成的作用。 方法　将人胆管癌细胞系QBC939细胞接种于鸡胚尿囊膜 (CAM)无血管区 ,给予整和素αvβ3单克隆抗体 ,观察其对人胆管癌血管生成及肿瘤生长的影响。结果　整合素αvβ3单克隆抗体组血管数目在给予抗体后第 2～ 8天均显著低于磷酸盐缓冲液 (PBS)对照组 (P <0 .0 5) ,光镜下瘤细胞分布稀疏 ,瘤组织新生血管腔减少。结论　整合素αvβ3单克隆抗体能够抑制胆管癌新生血管的生成 ,具有显著的抗肿瘤作用。     

A monoclonal antibody against the surface of osteoblasts recognizes alkaline phosphatase isoenzymes in bone, liver, kidney, and intestine

Monoclonal antibodies against the surface of embryonic osteogenic cells have been used to characterize the osteoblastic lineage. One antibody, SB-1, reacts in frozen sections with a family of cells in bone, liver, kidney, and intestine which are identically stained by the histochemical substrate for alkaline phosphatase. In this report, biochemical and immunochemical evidence is presented to indicate that SB-1 is directed against an epitope on alkaline phosphatase which is shared by isoenzymes in a variety of chick tissues. In a solid-phase assay system, high dilutions (1:10(5] of ascites fluid were found to give significant binding of SB-1 to alkaline phosphatase extracted from chick limb or intestine. Partial purification of intestinal alkaline phosphatase on a Sepharose CL-6B column results in the co-elution of alkaline phosphatase enzyme activity and antibody-binding material; this indicates that SB-1 recognizes intestinal alkaline phosphatase rather than an impurity in the crude preparation. Furthermore, Western immunoblots of chick calvarial bone extract electrophoresed on a 5-20% SDS-polyacrylamide gel show that SB-1 reacts with a single 155 kD band which also is stained by the alkaline phosphatase histochemical substrate. In a similar set of experiments, SB-1 reacts with an intestinal alkaline phosphatase isoenzyme whose molecular weight is approximately 185 kD. From these studies, we conclude that SB-1 is specifically reactive with alkaline phosphatase isoenzymes present in bone, liver, kidney, cartilage, and intestine. The reactive epitope is stable to SDS denaturation, not associated with the active site of the enzyme, and dependent on disulfide bonds which impart secondary structure to the protein.     

单克隆抗体OC_(859)治疗对卵巢癌患者生存率及免疫系统的影响

目的探讨单克隆抗体(单抗)OC859治疗对卵巢癌患者生存率及免疫系统的影响。方法对用单抗OC859治疗105例(单抗组)及未用单抗的126例(对照组)卵巢癌患者进行回顾性分析,比较两组患者的生存率。并测定单抗组部分患者血清人抗鼠抗体(HAMA)(25例)和T细胞亚群(15例)的改变。结果两组年龄、满意的肿瘤细胞减灭术比例、病理类型、分期、分化均无显著性差异。单抗组平均化疗10.9疗程,对照组平均化疗8.2疗程,两组有显著性差异(P<0.01)。单抗组平均生存时间、3及5年生存率分别为(91±6)个月、65.7%和62.2%,而对照组分别为(62±7)个月、41.1%和36.2%,均有极显著性差异(P均<0.001)。单抗组治疗后HAMA滴度明显升高。在单抗治疗前患者外周血CD4/CD8比值低于正常水平,单抗治疗一次后CD4/CD8比值大部分达正常水平,治疗两次后全部达正常水平。结论单抗OC859治疗使卵巢癌患者的3及5年生存率均明显提高,患者的免疫系统均有明显改变。在手术和化疗的基础上单抗OC859有助于卵巢癌的治疗。     

抗CD25单克隆抗体对肾移植受者末梢血淋巴细胞的影响

目的　探讨抗CD2 5单克隆抗体 (舒莱 )对肾移植受者末梢血活化T细胞的抑制作用。　方法　 4 6例肾移植受者随机分为舒莱治疗组 ( 2 3例 )和对照组 ( 2 3例 )。免疫抑制剂方案为新山地明胶囊 (Neoral)、硫唑嘌呤 (Aza)和泼尼松 (Pred) ,舒莱治疗组术前 2h和术后 4d各静脉滴注舒莱 2 0mg。应用流式细胞仪对 4 6例受者手术前后末梢血中不同表型淋巴细胞进行连续动态观察。 　结果　与对照组比较 ,舒莱组活化T细胞 (CD 2 5)在用药后 2 4h明显下降 ,从用药前的 ( 17.0 0± 3.70 ) %降至 ( 3.30± 2 .4 3) % ,1周后降至 ( 2 .5 2± 1.0 9) % ,并在整个观察过程中呈低水平表达 (P <0 .0 1) ;淋巴细胞总数和T细胞 (CD 3 CD-19)总数无明显变化 ;B淋巴细胞 (CD-3 CD 19)、NK细胞 (CD-3 CD 16CD 56)和非HLA限制性细胞毒性T细胞 (CD 3 CD 16CD 56)未见明显升高。　结论　舒莱对活化T细胞有明显抑制作用 ,其机理为克隆封闭而非杀伤或清除作用